87
Participants
Start Date
July 7, 2022
Primary Completion Date
June 10, 2024
Study Completion Date
June 10, 2024
Adalimumab
Subcutaneous Injection
Peking University First Hospital /ID# 243055, Beijing
Beijing Tongren Hospital, CMU /ID# 243054, Beijing
Shanghai General hospital /ID# 247252, Shanghai
Tianjin Medical University Eye Hospital /ID# 243056, Tianjin
The second affiliated hospital of Zhejiang University school of medicine /ID# 247251, Hangzhou
Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253, Wenzhou
Xi'an people's hospital/Xi'an fourth hospital /ID# 243371, Xi'an
Lead Sponsor
AbbVie
INDUSTRY